0000811212-13-000013.txt : 20130724 0000811212-13-000013.hdr.sgml : 20130724 20130723180644 ACCESSION NUMBER: 0000811212-13-000013 CONFORMED SUBMISSION TYPE: 425 PUBLIC DOCUMENT COUNT: 5 FILED AS OF DATE: 20130724 DATE AS OF CHANGE: 20130723 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: THERMOGENESIS CORP CENTRAL INDEX KEY: 0000811212 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY APPARATUS & FURNITURE [3821] IRS NUMBER: 943018487 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 425 SEC ACT: 1934 Act SEC FILE NUMBER: 333-82900 FILM NUMBER: 13982127 BUSINESS ADDRESS: STREET 1: 2711 CITRUS ROAD CITY: RANCHO CORDOVA STATE: CA ZIP: 95742 BUSINESS PHONE: 9168585100 MAIL ADDRESS: STREET 1: 2711 CITRUS ROAD CITY: RANCHO CORDOVA STATE: CA ZIP: 95742 FORMER COMPANY: FORMER CONFORMED NAME: INSTA COOL INC OF NORTH AMERICA DATE OF NAME CHANGE: 19920703 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: THERMOGENESIS CORP CENTRAL INDEX KEY: 0000811212 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY APPARATUS & FURNITURE [3821] IRS NUMBER: 943018487 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 425 BUSINESS ADDRESS: STREET 1: 2711 CITRUS ROAD CITY: RANCHO CORDOVA STATE: CA ZIP: 95742 BUSINESS PHONE: 9168585100 MAIL ADDRESS: STREET 1: 2711 CITRUS ROAD CITY: RANCHO CORDOVA STATE: CA ZIP: 95742 FORMER COMPANY: FORMER CONFORMED NAME: INSTA COOL INC OF NORTH AMERICA DATE OF NAME CHANGE: 19920703 425 1 form8-k.htm FILING OF CEO LETTERS form8-k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  July 23, 2013


THERMOGENESIS CORP.
(Exact name of registrant as specified in its charter)


Delaware
  
333-82900
  
94-3018487
(State or other jurisdiction of incorporation or organization)
  
(Commission File Number)
  
(I.R.S. Employer Identification No.)

2711 Citrus Road
Rancho Cordova, California  95742
(Address and telephone number of principal executive offices) (Zip Code)

(916) 858-5100
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[x]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



 
- 1 -
 


Item 9.01 Financial Statements and Exhibits.

(d)  Exhibits.

99.1  
Letter from ThermoGenesis CEO titled, “Cesca Therapeutics is Coming.”
99.2  
Letter from TotipotentRX Chairman and CEO titled, “Cesca Therapeutics is Coming.”

 
- 2 -
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


   
THERMOGENESIS CORP.,
  
   
a Delaware Corporation
  
       
       
 
Dated:  July 23, 2013
/s/ Matthew T. Plavan
  
   
Matthew T. Plavan
  
   
Chief Executive Officer
  
       


- 3 -
 EX-99.1 2 ex99.htm THERMOGENESIS CEO LETTER ex99.htm
Exhibit 99.1
 
Filed by: ThermoGenesis Corp.
Pursuant to Rule 425 under the Securities Act of 1933
Subject Company: ThermoGenesis Corp.
Commission File No.: 333-82900

 
Cesca Therapeutics is Coming
 
We are pleased to announce that ThermoGenesis and TotipotentRx will soon merge to create one of the first fully integrated regenerative medicine companies.  The combined company joins ThermoGenesis’ best-in-class cell-based device technologies with TotipotentRx’s cell therapeutic kits and protocols to offer clinically validated, commercially scalable, point-of-care autologous cell therapies for major therapeutic markets.

The combined company is expected to be named Cesca Therapeutics ("Clinical Excellence in Stem Cell Applications") and will be headquartered in Rancho Cordova, CA.  Cesca will continue to trade on NASDAQ under the ticker symbol KOOL.

Regenerative medicine is one of the fastest growing areas of modern medicine and is widely expected to become a major component of our future global healthcare system.  Cesca will offer safe and effective therapies that are backed by clinical evidence, use patient- and regulator-friendly autologous cells, and can be delivered at the bedside, in less than an hour – all at a fraction of the cost of other cell therapy offerings.

We invite you to learn more about the ThermoGenesis/TotipotentRx merger and its many benefits by exploring our website at www.thermogenesis.com  and the TotipotentRx website at www.totipotentrx.com.

Thank you for your continued support and we look forward to creating value and opportunity for all of our stakeholders.
 
 
Matthew T. Plavan
Chief Executive Officer, ThermoGenesis Corp.

Read the press release

Read the FAQ

View the corporate presentation

 
 
- 1 -
 
Non-Solicitation
This letter and the information contained herein shall not constitute an offer to sell, buy or exchange or the solicitation of an offer to sell, buy or exchange any securities, nor shall there be any sale, purchase or exchange of securities in any jurisdiction in which such offer, solicitation, sale, purchase or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.  No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Additional Information
In connection with the merger, ThermoGenesis intends to file a registration statement (including a prospectus) on Form S-4 with the Securities and Exchange Commission.  Holders of ThermoGenesis Common Stock and TotipotentRx Corporation common stock are urged to read the proxy statement/prospectus and any other relevant documents when filed because they contain important information about ThermoGenesis, TotipotentRx and the merger.  A proxy statement will be sent to holders of our Common Stock and a proxy statement/prospectus will be sent to holders of TotipotentRx Corporation common stock.  When filed, the proxy statement/prospectus and other documents relating to the proposed merger can be obtained free of charge from the SEC’s website at www.sec.gov.  These documents can also be obtained free of charge from ThermoGenesis upon written request to ThermoGenesis, Investor Relations, 2711 Citrus Road Rancho Cordova, CA 95742.

Forward Looking Statement
This letter contains forward-looking statements. Such forward-looking statements include but are not limited to that the proposed merger will be consummated, that regenerative medicine will become a major component of the future global healthcare system, and that the combined company will be able to offer safe and effective therapies in a short period of time and at a fraction of the cost of other typical cell therapy models.   These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements.  A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

ThermoGenesis Corp.
Web site: http://www.thermogenesis.com
Contact: Investor Relations
+1-916-858-5107, or
ir@thermogenesis.com
 
- 2 -
 EX-99.2 3 ex99_2.htm TOTIPOTENTRX CHAIRMAN AND CEO LETTER ex99_2.htm
Exhibit 99.2
 
Filed by: ThermoGenesis Corp.
Pursuant to Rule 425 under the Securities Act of 1933
Subject Company: ThermoGenesis Corp.
Commission File No.: 333-82900

 
Cesca Therapeutics is Coming
 
We are pleased to announce that TotipotentRx and ThermoGenesis will soon merge to create one of the first fully integrated regenerative medicine companies.  The combined company joins TotipotentRx’s cell therapeutic kits and protocols with ThermoGenesis’ best-in-class cell-based device technologies to offer clinically validated, commercially scalable, point-of-care autologous cell therapies for major therapeutic markets.

The combined company is expected to be named Cesca Therapeutics ("Clinical Excellence in Stem Cell Applications") and will be headquartered in Rancho Cordova, CA.  Cesca will continue to trade on NASDAQ under the ticker symbol KOOL.

Regenerative medicine is one of the fastest growing areas of modern medicine and is widely expected to become a major component of our future global healthcare system.  Cesca will offer safe and effective therapies that are backed by clinical evidence, use patient- and regulator-friendly autologous cells and can be delivered at the bedside, in less than an hour – all at a fraction of the cost of other cell therapy offerings.

We invite you to learn more about the ThermoGenesis/TotipotentRx merger and its many benefits by exploring our website at www.totipotentrx.com and the ThermoGenesis website at www.thermogenesis.com.

Thank you for your continued support and we look forward to creating value and opportunity for all of our stakeholders.

Sincerely,
 
Kenneth L. Harris
Chairman and Chief Executive Officer, TotipotentRx Corporation


Read the press release

Read the FAQ

View the corporate presentation

 
- 1 -
 


 
Non-Solicitation
This letter and the information contained herein shall not constitute an offer to sell, buy or exchange or the solicitation of an offer to sell, buy or exchange any securities, nor shall there be any sale, purchase or exchange of securities in any jurisdiction in which such offer, solicitation, sale, purchase or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.  No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Additional Information
In connection with the merger, ThermoGenesis intends to file a registration statement (including a prospectus) on Form S-4 with the Securities and Exchange Commission.  Holders of ThermoGenesis Common Stock and TotipotentRx Corporation common stock are urged to read the proxy statement/prospectus and any other relevant documents when filed because they contain important information about ThermoGenesis, TotipotentRx and the merger.  A proxy statement will be sent to holders of ThermoGenesis common stock and a proxy statement/prospectus will be sent to holders of TotipotentRx Corporation common stock.  When filed, the proxy statement/prospectus and other documents relating to the proposed merger can be obtained free of charge from the SEC’s website at www.sec.gov.  These documents can also be obtained free of charge from TotipotentRX upon written request to Investor Relations, TotipotentRX Corporation, 548 S. Spring Street, Ste 210, Los Angeles, CA 90013.

Forward Looking Statement
This letter contains forward-looking statements. Such forward-looking statements include but are not limited to that the proposed merger will be consummated, that regenerative medicine will become a major component of the future global healthcare system, and that the combined company will be able to offer safe and effective therapies in a short period of time and at a fraction of the cost of other typical cell therapy models.   These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements.  A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by the forward-looking statement will be set forth in the proxy statement/prospectus, and you should consider each of those factors when evaluating the forward-looking statements.

TotipotentRX Corporation
Web site: http://www.totipotentrx.com
+1-213.221.7373
 
- 2 -

 GRAPHIC 4 ex990.jpg begin 644 ex990.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``24DJ``@````$`!H!!0`! M````/@```!L!!0`!````1@```"@!`P`!`````@`!`3$!`@`0````3@`````` M``!@`````0```&`````!````4&%I;G0N3D54('8U+C`P`/_;`$,``@$!`0$! M`@$!`0("`@("!`,"`@("!00$`P0&!08&!@4&!@8'"0@&!PD'!@8("P@)"@H* M"@H&"`L,"PH,"0H*"O_;`$,!`@("`@("!0,#!0H'!@<*"@H*"@H*"@H*"@H* M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"O_``!$(`#8` M>@,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_ MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-CH.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($ M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B M7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X MN;K"P\3%QL?(RKR\_3U]O?X^?K_V@`,`P$` M`A$#$0`_`/W\HHHH`***Q_'_`(]\+_#+PA>^./&6I"UT^Q0&63&69F8(D:*. M7=W9451RS,`,DB@#8KAOCU^T7\*_VL3K-J=ZMCH&B:7927FI:U M>L"4M;.UB#27$I`)VJ,*JLS%55F&?^U!^TSX3_9B\!6_B/5='O-1R%0FO*O!'@O0?@#XT3]I/]K#7% M\8_'/Q;:-8:1HWARWDNSI5FSAO[)T:U/S1VZG:9[QPGFLOFSO'&J)$`='\,? MVIOVA?%/QZT'X9?$W]E"+P?H7BK0=0U31+^X\;1WFK6T=J;;(O[&&W\FUW?: M44%+J;#C:>N:][KSGX-?#+Q?9^*]9^-GQ;N87\4^(H8K:#3+9Q)!H&FQY:.P MB?`\QB[/)++QOD8`#9&F/1J`"BBH=0U"PTFQFU35+V*VMK>)I+BXGD")$@&2 MS,>``.23TH`FHKY:^)?_``5N_9U\.?$FS^"WP0\&>,_C%XPOI8UBT'X9Z7#< M%(W)`N7GNIH(1;#!W7"NT2]"P)`/U'$[21+(\3(64$HQ&5/H<<4`.HHHH`** M**`"BBN$_:+_`&E?@K^RA\,+WXO_`!W\_T?Q?9::EG-?O' M)I>I6^HP"\AM@SVUK-):K"T\FU5\S()("F7X!^-OVH_V_K2_^)'Q+\(^(O@O M\(KGRF\'>'XK[[)XH\46I#[[K4)%&_2K=@8S'!`R7!P6:95(5N/^#WPE^#?[ M5/Q#E^(&D>$/#^B?LV_"O77NO"=E;QK!:^-/$MHY^T:_=OD"XM+21&2!Y"WG M3I+<,6$<#D`\E^$WC_\`;\^-?QNN?VL_VE_V8/B%\/CKNBQZ?\-[+P?H=EX@ MOO"VB3K'([(T\P@M+VX<@W$LUM*X2*.()$(V+?3'PQ^)W@KX-SZAJW@S]AKX MWW6JZ@T8UGQ-JFC6UYJ6I-@,HEN;F^,TB+N("#]W'RJ*H&*\9^/7_!P_^RQX M,U_6?!W[,_@?6_C!>Z;JVG:/;ZUX85SH-QJ=W-(GV/?:[FCV.57?M`!VG_#6/CJX`72OV'?C)=2D_ZHVFAV_'KNN-4C3\-V M?:J,G[2_[4>IV9F\._\`!/'QG9R".1L^*_''ARSC!!&T%K2_NV&>23MX`[GB MO*/BC^V;XK\6_';1O@3\+_B=?#2/"6KI;>+=;\.:1!<:KXXUJ`*[Z#I<+9CB MBCRK7]X<16X=8?,C8R/'VGQCU#5FTG3?$7[7B7-ZFN:I'9^%_@GX,G\Y;^1F M!Q?2%D^W^7'NEF#&.SBC5RZRA!*0#D8OVHO^"E7QQU9_#W[.7P2^#FG6Z7IB MN?%U]XPU'7M+M(PV&+216MBD\PP_[JV><*P"R-%G<-W7?^";WC?X\:DFJ?MH M?MJ>/O'%IY2A_!?A18/#'A]7P,NL5H&O2P895WO&=>QZUZ#XN_;U_8-^#<\7 M@WQ+^U3\.-)NK9!#;Z#;^)[1KE%7Y0B6L+F3`QC`7@#VK(N/^"F7[(Z60U'3 M=:\_`;&>?L^G/@>_2@#TCX&_LY?`S]FGPF?!/P)^%^D>& M=/>3S+I=.ML2W:>9LR7$I[R2,SGN37:UX1I?_``4<_9MUJ>2UTS0_BS+) M$@:1/^%`>,%(!.,\Z6._%.N_^"BG[/VEZ6-7UKP;\8K*(L%_TG]GSQANR1TP MNEF@#W6BO!+K_@IE^Q[IJVQUOQAXJTQ[N(200ZM\+?$5K(5/&2DM@K+SUR!C MO4FI?\%-_P!A#1;H6.L_M':/9SE2PANK6YC?`7<3M:('A>3Z#F@#W>BO'K'] MNO\`9X\07HTKP)J/B;Q->N`8[;PYX#U:[!RP4;I4MO*B&2`6D=5'<@`FO7XW M9T5VB920"5;&1[<&@#R7]L[]J:Y_91^$R>+?#'P?\2?$+Q9K.H)I7@OP/X5L MS+=:OJ,B.R([XV6UNJHSRW$A"1HI/+;5;QG]FS_@GW\3?B!\1[3]K;_@I/XA MTKQC\08UAF\/^#[&,R:)X3927"Q*WRSR*YRK$;4*1L3-+&+@_85!(`R3P*`/ MG3]M/Q=XM^+7B[0OV"/A#K=UI^L>.["2_P#'OB&P8"3P[X3CD6.ZD5L@QW-X MS&SMV'S*6FF7_CW-._:4_P"";/P;_:=\-_#OX,>+=>U;2?A)X"VFX^$_AV06 M>E^(!"D:6=O>F/#O:P!"1;@A9"PWY"X+/^"?6F2?$1/B'^V7KK&;4/BGXTNE MT21R2;;PWI>$[7P;K'@R M>ZL[/5-6OX8UO&MU\W41Y'M%O;W4='T*SM+C4IQ/J,]M;)&]U*%"AY&4`NVU57+9.`!VH`^7-% M_P""??Q'_9C^`VE_"O\`8#\>^&/#/BVY6*R\2?%'QYHLFKW\%BH+'[);*R1Y M\PY6!F2%2[R,LDC.SZOA'_@E1^SCJ.JP>/\`]JN]UOXZ^-?LI@O/$GQ1O?M= MNZ%Q(8X=+C":?;1;P"$CMQT!)8C-?3=%`&#X#^&?P[^&>C1:%\/?AYH7AVSB M7$=CH6F16T*`=`JQHH'Y=ZWJ**`"BBB@`HHHH`****`"FR)YD;1YQN4C-%%` M'CG_``3WT^TT#]C?P+X-M+:.,^&].FT&X:)<)-/87,ME-,H[+))`\@SSA^>< BU[+110`4444`%%%%`!1110`4444`%%%%`!2%P#BBB@#_V3\_ ` end GRAPHIC 5 ex994.jpg begin 644 ex994.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``24DJ``@````$`!H!!0`! M````/@```!L!!0`!````1@```"@!`P`!`````@`!`3$!`@`0````3@`````` M``!@`````0```&`````!````4&%I;G0N3D54('8U+C`P`/_;`$,``@$!`0$! M`@$!`0("`@("!`,"`@("!00$`P0&!08&!@4&!@8'"0@&!PD'!@8("P@)"@H* M"@H&"`L,"PH,"0H*"O_;`$,!`@("`@("!0,#!0H'!@<*"@H*"@H*"@H*"@H* M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"O_``!$(`#,` M<0,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_ MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-CH.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($ M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B M7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X MN;K"P\3%QL?(RKR\_3U]O?X^?K_V@`,`P$` M`A$#$0`_`/W\HHHH`**\_P#V;?VDOAY^U-\/[GXB?#B'4;>WL==O='U"QU>V M6&ZM+NUE,T\.+=6'Q+U"6UU&]73I)Y+7,L4$)5DE41@S3(&9D<`'/&*^C*;BTDWU! M23;2Z!16%\,?B;X#^,WP_P!)^*?PP\2P:QH&NV2W6E:E;!@L\3=\,`RD$$%6 M`96!5@""*TM)U_0M?%RVA:U:7HL[N2UNS:7*R>1.AP\3[2=KJ>"IY'<5-F@N MF6Z***!A1110`4444`%%%%`!6;XR\8^%_A[X3U+QWXWUVVTS1]'L9;S4]1NY M-L5M!&I9Y&/8!036E7A__!13X#?$C]I#]E/6_AG\)X=*N];_`+1T[4;;1M=D M9;'5UM+R&Y:RG((^241E<-\I.`2H.Y7%)R28I-J+:/E3_@C-KNL_%GXP_'UM M,\3Z_P"&O"]I\7SXPTOP:=/-E/-%J@NGMS=%P7$#016[B)-FXPH69XR4;]$- M>U_0O"NB7?B;Q1K5IINFZ?;/<7^H7]RL,%M"BEGDDDZ1K>I^&_%WCZ&.QT\V:K:_;A-9 M+.MW&9'D01QJ)/F9CLPXK[7^'_[.7Q!UK5[;X@?M3_%Z;Q?KEO-YUAH.AQ2: M9X?TEMVX"*U5V>Z<,YPV(H++58UCM99>@6)+I M(\L6PK-'P.KI;+3_@U\ M6/$<4,,;!H[/12?ML31KU5#NG8*>WOD#D/\`@@#\3O$'Q.^`WQ5U[QO!-%X@ MU3XSZCKNKQ21E0KWUI9RG"L=P!=9#R.A')YQ\]_\%$_BQ\1/V??VO/V@?V8_ MA7\-M0UN^_:-T;PV-.M[+4F$ZM]FGM9A!$$?VX?$W[67QM\!?L_P#P%^'O@;7-7BL-7U;PA\2Y-3M5T7[-&MJJ1K!#YKEO M.C=A(JY&"&RV3T2I\U.4N]F`!C&.YYO9K^9'7SO^5GU917RQ!^S+_P5(-NVGW' M_!4#1%$L#,U^OP-T]IH)2W"(GV@(R*"<,PSP,J7[$GS/"^DV6C6_+$G]Q&)%[C'/`&!Q@`Y(_P`R_'_(.>7\K_#_`#/K M2BOF+X??LT?MF_LY_%+PUKWA/]KKQ)\4O!M[J7V7QKX8^($5L]U;6\BD"_L[ MI0C!HG$9:`Y#(9"`S[5KZ=J9)+9W*BV]U8****DH****`/B7]L;Q'H_[/W_! M6+X"_M`^+]9M=(\.>(O!/B'PUX@UF](CAMXK:&2\B$DA.%!EF0C..`Y&>^)UI\9?A[I_Q.TCP]J.FZ9K,0N='CU>#R;F>T8`QSO%R8A(/G5&.[8R%@ MC$HN=\>/V;/@;^TYX>TWPI\>/AU9^)-.TC68=5T^UO7D58KN+<$?]VREAAF# M(V4<$AE8<5W%:2E&45W,XQE&;?1GRE^T]_P2^N?VKM?\=7/Q#_;%^*%MH7BR M&W&E^$M,UV6/2]*DB5,!K0R&"YB+QI)L,:/NW'S-Q#+G?L`?M>_%6+XJ:E_P M3M_:XT.2W^)G@+11)I_B@RNT'C#38G\N.^C+C.\QF)F)8EV\PD*R.J_7U8VI M_#KP%K/C;3/B3JW@W3+GQ!HMM/;Z1K4UDC75G%,`)4CD(W(KA1D`\T>TO'ED M'LTI\T3Y7_;C_8Q\7?%[]OG]G3]I7P3X+NM1MO">MRP^,;NUU!+Y\7_X+,66K_L?_`+5/P>_X*2_#N*_MO)U:+0O'*:7F M,:C;1MYR0RE742-+`+B/#\$0Q@G"@5^E->:_M<_LM_#S]LKX#:S\`?B;)DD>PUG38+ZQ:5-K&&:-9$)4]#M89':M*LKP+X/TKX>^"-&\` MZ%),]EH>E6^GV;W+AI&BAB6-"Q``+;5&2`.>PK5K)VOH;(****0!1110`444 D4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110!__9 ` end